Tuesday, 17 November 2026Peptide medicines at the counter: price, coverage, supply, rules.

Reading as
What is this?
RulesUS

GLP 1 pregnancy guidance from ACOG says stop before trying to conceive

ACOG's first advice on GLP 1 drugs and pregnancy says patients should consider stopping one to two months before conceiving and avoid the drugs while pregnant. Human data are limited, and the advisory says nothing about how plans or online sellers handle a pause.

Editorial illustration for the story: GLP 1 pregnancy guidance from ACOG says stop before trying to conceive
Illustration: Peptide Town. Cut-paper collage, not data.

Who feels it

  • Patients Rethink

    If you may become pregnant, ask about stopping one to two months ahead, birth control on tirzepatide, and restarting after birth.

  • Prescribers Rethink

    ACOG advises counseling on limited data, a one to two month stop before conception and no use in pregnancy outside trials.

  • Sellers Adjust

    Online prescribers and compounders reach many reproductive age users; the advisory does not say how they should apply it.

  • Pharmacies Worth knowing

    Expect questions on oral contraceptives with tirzepatide and on GLP 1 use while breastfeeding.

  • Payers Worth knowing

    The advisory is silent on coverage, so pause and restart rules after pregnancy fall to each plan.

Women who take weight loss and diabetes injections now have formal advice on when to stop. The new GLP 1 pregnancy guidance from the American College of Obstetricians and Gynecologists, its first on the topic, says patients should consider stopping one to two months before trying to conceive and should not use the drugs while pregnant. NPR's Short Wave podcast revisited the advice on November 9 with Dr. Amy Valent of Oregon Health and Science University. The advisory is a professional standard, not a law or an FDA rule, but it shapes who stays on treatment and when.

What the ACOG advisory tells doctors

ACOG released the practice advisory in late October, and trade outlets including Healio reported it on October 23. According to the ACOG news release, ob gyns and other clinicians should tell patients that there are not enough safety data on GLP 1 use in pregnancy. They should advise patients to consider stopping one to two months before pregnancy, and the group recommends against use for the whole pregnancy. Contemporary OB/GYN reported that the only exception is use inside a clinical trial. The advisory also carries a table of every GLP 1 medicine and its half life, because these drugs stay in the body for a long time and can still be present when a pregnancy starts.

ItemWhat ACOG or the sources say
ReleasedLate October 2026, reported October 23
Before pregnancyConsider stopping one to two months ahead
During pregnancyRecommends against use except in a trial
BreastfeedingShared decision, not for preterm or newborn infants
Evidence baseLimited human data, concerning animal findings

The reasons are mostly about missing evidence. ACOG says that in animal studies, GLP 1 use in pregnancy was linked to lower fetal weight, restricted growth, abnormal bone development, and less eating and weight gain in the mother. Human data are thinner. Healio reported that early observational studies have not shown a clear rise in major birth defects after accidental exposure in the first trimester, but ACOG says those data do not prove the drugs are safe for longer use. The group called for confirming studies and registries that track mothers and babies, and said it will update the advice as research arrives. Dr. Yvette LaCoursiere is the lead author of the ACOG practice advisory, and Valent chairs the ACOG Clinical Consensus Committee for obstetrics.

Why Ozempic babies drew attention

The advisory lands in the middle of a social media story. "Ozempic babies" is the online name for pregnancies, planned and unplanned, that people link to these drugs. In its Short Wave episode, NPR said the medicines may raise fertility for some people, which can lead to more of both kinds of pregnancy. Becker's Hospital Review, summing up the research, noted reports that the drugs may support fertility indirectly through weight loss and may help regulate menstrual cycles in women with polycystic ovary syndrome, with trials still under way. None of this makes the drugs a fertility treatment. Healio reported that ACOG tied its advice to rising GLP 1 use among people of reproductive age and to the long half lives that raise the risk of exposure.

An international panel reviewed 34 studies and found none reporting a higher risk of birth defects among about 1,538 exposed pregnancies, Becker's reported.

The best human evidence so far is reassuring but narrow. An international panel reviewed 34 studies and found none reporting a higher risk of birth defects among about 1,538 exposed pregnancies, Becker's reported. Most of those exposures were accidental and limited to the first trimester. The same panel, which reported in August, had direct evidence for only 18 of its 32 clinical questions and found no clear support for any specific washout period before conception. That gap helps explain why the GLP 1 pregnancy guidance frames its one to two month window as something to consider rather than a firm rule. Valent described the trade off in the ACOG release: "there are risks associated with both taking the medication and discontinuing that people should consider." Stopping can bring weight regain, which may itself raise pregnancy risks.

Tirzepatide birth control and breastfeeding rules

One drug carries an extra warning that matters before any pregnancy. The FDA label for Zepbound, which contains tirzepatide, tells prescribers to advise women on birth control pills to switch to a non oral method or add a barrier method for four weeks after starting treatment and for four weeks after each dose increase. The label also says to stop Zepbound once a pregnancy is recognized. The August panel made a similar point, advising women on tirzepatide to use nonoral contraception, according to Becker's. For patients, this tirzepatide birth control step is easy to miss. The pill and the injection may come from different clinicians, and a plan to stop before conceiving depends on the pill working until the patient decides to try.

After birth the advice loosens. Epocrates, summarizing the advisory, said ACOG suggests clinicians decide on GLP 1 treatment during breastfeeding together with each patient, but recommend against it when the baby was born preterm or is within the first 28 days of life. Becker's reported that patients may be able to restart injectables while nursing with monitoring of the infant, and should avoid oral GLP 1 pills. The same Epocrates summary says weight should be watched before, during and after pregnancy, with support such as dietitian referral when needed. These are counseling points rather than coverage rules. Whether a health plan pays to restart treatment after a pregnancy gap is a separate question that the advisory does not address.

Compounded GLP 1 drugs and who gives the advice

The guidance assumes a clinician who knows the patient may become pregnant. Many users do not get the drugs that way. A USC and RAND preprint estimated that about 9 million US adults obtained GLP 1 drugs outside insurance and regular pharmacies, through online prescribers, med spas, compounders, foreign pharmacies or no prescription at all. The GLP 1 pregnancy guidance was written for ob gyns and other health professionals, and it is not known how online sellers will apply it. Compounded GLP 1 drugs are not FDA approved, so their strength and contents have not passed FDA review. In a recent recall of 22 compounded tirzepatide lots, the pharmacy said it could not be sure the drug was safe.

Money adds another layer. Coverage for weight loss use is already shrinking, with only 53% of US employers now paying for it, down from 57%, according to a survey cited in our report on employers dropping GLP 1 coverage. A patient who pauses treatment for a pregnancy and later wants to restart may face a plan that has changed its rules in the meantime. The advisory says nothing about prior authorization, cash prices or restart approvals, so those answers sit with each plan. Patients planning a pregnancy can ask both their prescriber and their insurer before they stop. This article is research reporting only and is not medical advice for any person.

Conclusion

The first GLP 1 pregnancy guidance from ACOG gives patients and doctors a shared starting point: consider stopping one to two months before conception, avoid the drugs in pregnancy, and decide on breastfeeding case by case. It rests on limited human data, and ACOG says it will revise it as studies arrive. What it cannot settle is access. People who get the drugs online or through compounders may never hear the advice, and the advisory is silent on how plans handle a pause.

Source ACOG practice advisory and news release on GLP 1 use in pregnancy and lactation, October 2026; NPR Short Wave, November 9, 2026; FDA Zepbound label

Spotted an error? Tell us through the contact form; we follow the corrections policy.